ACC 2022 – Bristol's rare hit could justify Myokardia

Bristol Myers Squibb paid $13bn for mavacamten’s developer, Myokardia, so it needs the project to be a hit. Today the company got a boost with impressive results from Valor-HCM study, in a sicker population of hypertrophic cardiomyopathy patients than the one in which the asset had previously been tested.

Bristol looks like it will have its work cut out to hit the $4bn-plus peak sales target it has set for mavacamten but, as with many rare diseases, the group hopes that having a therapy available will spur more patients to be diagnosed.